

Original Research Article

Study of price variations of anti-epileptic drugs available in different brands in Indian pharmaceutical market

Purnendu Arya¹, Ratan Kumar^{2*}, Akash Chandra¹, Lalit Mohan¹

¹Department of Pharmacology, IGIMS, Patna, Bihar, India

²Department of Pharmacology, M. G. M Medical College, Jamshedpur, Jharkhand, India

Received: 07 August 2018

Accepted: 21 October 2018

*Correspondence:

Dr. Ratan Kumar,

E-mail: drratan58@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Background: To analyze the cost ratio and percentage cost variations in different brands of the commonly prescribed anti-epileptic drugs available in Indian pharmaceutical market.

Methods: The maximum and minimum price of each brand of the drug given in INR was noted by using CIMS January to April 2018 edition and drug today April to June 2018 Vol-1. The cost ratio and the percentage cost variation for individual drug brands was calculated. The cost of one bottle in case of 100ml syrup and 10 tablets/capsules was calculated in case of oral drugs and the cost of one 1 vial or ampoule was noted in case of injectable drugs. At last the cost ratio and percentage cost variation of various brands was compared.

Results: After calculation of cost ratio and percentage cost variation for each brand of anti-epileptic drug tablet clonazepam (2mg) shows highest cost ratio and percentage cost variation as: 10.41 and 941.66, carbamazepine (200mg SR tablet) shows lowest cost ratio and percentage cost variation as: 1.09 and 9.32.

Conclusions: Epilepsy is the most common neurological disorder and Epileptic drugs are to be prescribed for prolonged period. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment. There is a wide difference in the cost of different brands of anti-epileptic drugs available in India. The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy.

Keywords: Anti-Epileptic drugs, Cost ratio, Percentage cost variation

INTRODUCTION

Epilepsy is a group of neurological disorders which is characterized by seizures, loss of consciousness, muscular contraction.¹ The cause of most cases of epilepsy is unknown.² Some cases occur as the result of brain injury, stroke, brain tumors, infections of the brain, and birth defects through a process known as epileptogenesis.² Known genetic mutations also causes some cases of epilepsy.³

The diagnosis involves ruling out other conditions such as alcohol withdrawal or electrolyte problems.³ Epileptic seizures are the result of excessive and

abnormal neuronal activity in the cortex of the brain.⁴ In 2015, about 39 million people have epilepsy.⁵ Nearly 80% of cases occur in the developing world. In 2015, it resulted in 125,000 deaths up from 112,000 deaths in 1990.⁶ Epilepsy is more common in older people.⁷ In the developed world, onset of new cases occurs most frequently in babies and the elderly.⁸ In the developing world, onset is more common in older children and young adults, due to differences in the frequency of the underlying causes.⁹

The diagnosis of epilepsy is typically made based on observation of the seizure onset and the underlying cause.¹⁰ An electroencephalogram (EEG) to look for

abnormal patterns of brain waves and neuroimaging (CT scan or MRI) to look at the structure of the brain are also usually part of the workup. Video and EEG monitoring may be useful in difficult cases. The mainstay treatment of epilepsy is anticonvulsant medications, possibly for the person's entire life.¹⁰

The choice of anticonvulsant is based on seizure type, epilepsy syndrome, other medications used, other health problems, and the person's age and lifestyle.¹¹ A single medication is recommended initially.¹² If this is not effective, switching to a single other medication is recommended.¹³

There are a number of medications available including phenytoin, carbamazepine and valproate. Low-quality evidence suggests that phenytoin, carbamazepine, and valproate may be equally effective in both focal and generalized seizures.¹⁴

Controlled release carbamazepine appears to work as well as immediate release carbamazepine and may have fewer side effects.¹⁵ Patients from poor socioeconomic background must have access to the correct drug at the nominal price. Costly drugs can lead to economic burden which results in decreased compliance or even non-compliance. Non compliance leads to incomplete treatment which tends to increased morbidity. There is a gross variation in the cost of different brands of same generic drugs available in Indian pharmaceutical market. Increase in the patient medication cost was found to be associated with decrease adherence to prescription medication.¹⁶

Hence the present study was conducted to evaluate the cost variation amongst the different brands of anti-epileptic drugs available in Indian pharmaceutical market.

METHODS

Price in Indian rupees (INR) of anti-epileptic drugs manufactured by different pharmaceutical companies in India, in the different strength were obtained from Current index of medical specialists (CIMS) January to April 2018 edition and from drug today April to June 2018, vol-1 as they are readily available source of drug information and are updated regularly.

The cost of 10 tablets/capsules, syrup of one bottle and that of one ampoule/vial were calculated. The cost of drugs were also crosschecked at pharmacy or retail drug store. Difference in the maximum and minimum price of the same drug formulation manufactured by different pharmaceutical companies and percentage variations in prices were calculated.

The cost of injectable drugs and oral drugs in forms of table, capsule and syrup should be calculated separately. The cost ratio, calculated as the ratio of the costlier brand

to that of the cheapest brand of the same drug, calculated as follows:

Cost ratio= Price of the costliest brand/Price of the least costly brand

The percentage cost variation of each drug should be calculated as follows:

Percentage cost variation = (Maximum cost-Minimum cost/minimum cost) x 100

Maximum percentage cost variation and cost ratio of a particular drug should be noted down. Minimum percentage cost variation and cost ratio of a particular drug should be noted down.

Inclusion criteria

- Drugs belong to group of anti-epileptic only should be included.
- Doses form of anti-epileptic drugs will be capsule/tablet, syrup, ampoule/vial.
- Drugs belong to branded manufacturing companies should be included.
- Drugs belong to same and different strength should be included.

Exclusion criteria

- Anti-Epileptic drugs in combinations with other drugs should be excluded.
- Drugs belong to bogus manufacturing companies should be excluded.

RESULTS

Tablet clonazepam (2mg) shows highest cost ratio and percentage cost variation as: 10.41 and 941.66, Tablet carbamazepine (200mg SR tablet) shows lowest cost ratio and percentage cost variation as: 1.09 and 9.32. We can prefer those drug who possess cost ratio less than 2 and percentage cost variation less than 100.

In this case we should prefer tablet carbamazepine 200mg SR tablet because it shows lowest cost ratio and lowest percentage cost variations. Epilepsy is the most common disorder of central nervous system and oral medicines are to be prescribed for prolonged period. If a costly brand is prescribed, the patients have to pay more money unnecessarily for their treatment.

The clinicians prescribing these drugs should be aware of these variations in cost to reduce the cost of drug therapy. In India, doctors have less awareness in the cost difference of different brands of the same drug. It is felt that physicians could provide better services and reduce costs of drugs if information about drug prices was readily available.

Hence, authors need to draw attention to the prices of various drug formulation brands available to reduce the cost of therapy. The treating physician should be made

aware of the cheapest drug available among the various brands so that the patient bears lesser burden of treatment cost.

Table 1: Cost ratio and percentage cost variation of anti-epileptic drugs available in Indian pharmaceutical market.

| Drug | Dose | No. of brands | Maximum price (Rs) | Minimum price (Rs) | Price ratio | % Price variation |
|------------------|---------------------------|---------------|--------------------|--------------------|-------------|-------------------|
| Carbamazepine | 200mg CR tablet | 3 | 21.40 | 14.30 | 1.49 | 49.65 |
| | 200mg ER tablet | 2 | 23.50 | 15.79 | 1.48 | 48.82 |
| | 200mg SR tablet | 2 | 15 | 13.72 | 1.09 | 9.32 |
| | 200mg tablet | 20 | 21.40 | 11 | 1.94 | 94.54 |
| | 400mg CR tablet | 2 | 41.70 | 26.50 | 1.57 | 57.35 |
| | 400mg ER tablet | 2 | 45.75 | 31.02 | 1.47 | 47.48 |
| | 400mg tablet | 8 | 41.70 | 24.24 | 1.72 | 72.02 |
| Sodium Valproate | 100mg tablet | 11 | 11.21 | 6.50 | 1.72 | 72.46 |
| | 200mg tablet | 14 | 42 | 21.85 | 1.92 | 92.21 |
| | 200mg/5ml syrup | 5 | 65 | 47.50 | 1.36 | 36.84 |
| | 250mg tablet | 4 | 64 | 45 | 1.42 | 42.22 |
| | 500mg tablet | 13 | 90 | 46.81 | 1.92 | 92.26 |
| Phenytoin | 500mg ER tablet | 5 | 118 | 58 | 2.03 | 103.44 |
| | 500mg CR tablet | 6 | 90 | 32 | 2.81 | 181.25 |
| | 50mg tablet | 4 | 13.50 | 7.26 | 1.85 | 85.95 |
| | 100mg tablet | 10 | 21.1 | 5.71 | 3.69 | 269.52 |
| Pregabalin | 300mg ER tab/cap | 3 | 59 | 50.19 | 1.17 | 17.55 |
| | Inj 50mg/ml (2ml ampoule) | 4 | 120.90 | 58 | 2.08 | 108.44 |
| | 75mg capsule | 21 | 97 | 54.89 | 1.76 | 76.71 |
| Clonazepam | 150mg capsule | 13 | 159 | 115 | 1.38 | 38.26 |
| | 0.25 mg tablet | 24 | 22 | 9.10 | 2.41 | 141.75 |
| | 0.5mg tablet | 44 | 36 | 9.90 | 3.63 | 263.63 |
| | 1mg tablet | 25 | 43 | 18.29 | 2.35 | 678.29 |
| Lamotrigine | 2mg tablet | 31 | 75 | 7.20 | 10.41 | 941.66 |
| | 25mg tablet | 9 | 58 | 21 | 2.76 | 176.19 |
| | 50mg tablet | 9 | 90 | 39 | 2.30 | 130.76 |
| Gabapentin | 100mg tablet | 8 | 157 | 69 | 2.27 | 127.53 |
| | 100mg tab/cap | 5 | 47.50 | 42 | 1.13 | 13.09 |
| Levetiracetam | 300mg tab/cap | 12 | 312.87 | 69.90 | 4.47 | 347.59 |
| | 250mg tablet | 9 | 82 | 44 | 1.86 | 86.36 |
| Topiramate | 500 mg tablet | 17 | 164 | 75 | 2.18 | 118.66 |
| | Inj 100mg/ml | 6 | 147 | 40 | 3.67 | 267.5 |
| | 25mg tablet | 4 | 56 | 30 | 1.86 | 86.66 |
| | 50mg tablet | 6 | 87 | 58 | 1.5 | 50 |
| | 100mg tablet | 3 | 15 | 108 | 1.42 | 42.59 |

DISCUSSION

The Indian market has over 100,000 formulations and there is no system of registration of medicines. More than one company sells a particular drug under different brand names apart from the innovator company. This situation has led to greater price variation among drugs marketed. These wide variations in the prices of different formulations of the same drug have severe economic implications in India. Unlike developed countries, people in developing countries pay the cost of medicines out-of-

pocket. Many poor people frequently face a choice between buying medicines or buying food or other necessities due to limited resources and high pricing of drug. So, medicine prices do matter. In India more than 80% health financing is borne by patients.¹⁷ Studies have shown that providing a manual of comparative drug prices annotated with prescribing advice to physicians reduced their patients drug expense especially in a disease like hypertension which needs long term treatment.¹⁸ Costs of drugs are controlled by the drug cost control order 2013 (DPCO).¹⁹

Hence, it was need to draw attention to the prices of various drug formulation brands available to reduce the cost of therapy.²⁰ The treating physician should be made aware of the cheapest drug available among the various brands so that the patient bears lesser burden of treatment cost.²¹

CONCLUSION

In now dasys prices of few drugs are under government control through DPCO (Drug price control order). The physician should always remember that he should not avoid treating the patients with a particular drug because it is expensive and should rather balance his therapeutic decisions in prescribing a particular drug by considering the patients socioeconomic status. There is a strong need to create awareness about this huge price variation among the general public, health care providers, health care payers, government agencies, policy makers, pharmacists for appropriate intervention to reduce economic burden on patients as well as the healthcare system.

REFERENCES

1. Chang BS, Lowenstein DH. Epilepsy. *N Engl J Med.* 2003 Sep 25;349(13):1257-66.
2. WHO. Epilepsy Fact sheet. February 2016. Available at: <http://www.who.int/news-room/fact-sheets/detail/epilepsy>. Accessed 4 March 2016.
3. Longo DL. 369 Seizures and Epilepsy. *Harrison's principles of internal medicine (18th ed.)*. McGraw-Hill. 2012:3258.
4. Fisher R, van Emde Boas W, Blume W, Elger C, Genton P, Lee P, Engel J. Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE). *Epilepsia.* 2005;46(4):470-2.
5. Vos T, Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. *The Lancet.* 2016 Oct 8;388(10053):1545-602.
6. Wang H, Naghavi M, Allen C, Barber RM, Bhutta ZA, Carter A, et al. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. *The lancet.* 2016 Oct 8;388(10053):1459-544.
7. Browne TR, Holmes GL. *Handbook of epilepsy.* 4th ed. Philadelphia: Lippincott Williams and Wilkins;2008:288. Accessed 29 May 2016.
8. Wyllie E. *Wyllie's treatment of epilepsy: principles and practice.* 5th ed. Philadelphia: Wolters Kluwer/Lippincott Williams and Wilkins;2010. Accessed 24 June 2016.
9. Newton CR, Garcia HH. Epilepsy in poor regions of the world. *The Lancet.* 2012 Sep 29;380(9848):1193-201.
10. National Clinical Guideline Centre. *The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care.* National Institute for Health and Clinical Excellence, 2012. Accessed 16 December 2013.
11. National Clinical Guideline Centre. *The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care.* National Institute for Health and Clinical Excellence. Accessed 16 December 2013.
12. Wyllie E. *Wyllie's treatment of epilepsy: principles and practice.* Lippincott Williams and Wilkins;2012:187.
13. National Clinical Guideline Centre. *The epilepsies: The diagnosis and management of the epilepsies in adults and children in primary and secondary care.* National Institute for Health and Clinical Excellence. Accessed 16 December 2013.
14. Nevitt SJ, Marson AG, Weston J, Smith CT. Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic-clonic seizures: an individual participant data review. *Cochrane Database of Systematic Reviews.* 2016(4).
15. Powell G, Saunders M, Rigby A, Marson AG. Immediate-release versus controlled-release carbamazepine in the treatment of epilepsy. *The Cochrane Library.* 2016 Jan 1.
16. Eaddy MT, Cook CL, O'Day K, Burch SP, Cantrell CR. How patients cost-sharing trends affects adherence and out comes: a literature review. *PT.* 2012;37:45-55.
17. Thomas M. Rational drug use and essential drug concept. In: Parthasarathi G, Nyfort Hasen K, Editors. *A Textbook of Clinical Pharmacy Practice.* 1st ed. Himayatnagar, Hyderabad: Orient Longman;2004:723.
18. Rataboli PV, Garg A. Confusing brand names: nightmare of medical profession. *J Postgrad Med.* 2005;51:13-6.
19. Drug Cost Control, Government of India; Order, 2013. Available at: <http://www.nppaindia.nic.in/DPCO2013.pdf>.
20. Vieira JL, Portal VL, Moriguchi EH. How much do we pay for a benefit? A descriptive cost analysis of the use of statins. The need for a national cost-effectiveness analysis. *Arq Bras Cardiol.* 2001;76(5):409-18
21. Kumar L, Dinkar JK, Mohan L, Dikshit H. Costvariation analysis of antimalarial drugs available in India. *Int J Rese in Med Sci.* 2017;5(9):4051-4.

Cite this article as: Arya P, Kumar R, Chandra A, Mohan L. Study of price variations of anti-epileptic drugs available in different brands in Indian pharmaceutical market. *Int J Res Med Sci* 2018;6:4102-5.